LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis.
The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis:
WATCH OUR MANIFESTO VIDEO HERE
The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com
The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases.
October 2020 marks the second year of a three-year ‘Connected, Informed, United’ IFPAtheme, with the theme of ‘Be Informed’ the focus of this year.
Henrik Kyndlev, Director of Global External Communications at LEO Pharma, said: “We’re proud to support IFPA’s important initiative, and are keen to do our part in helping people ‘Be Informed’ about psoriasis this year.”
“Our campaign supports this theme in a very simple but powerful way - namely by bringing attention to some everyday psoriasis stories of real-life patients. After all, psoriasis is not just about a single day, but is an everyday challenge for many patients.”
The #everydaypsoriasis campaign centres around three audio-interviews with psoriasis patients, whose stories are brought to life with short animations depicting the everyday challenges they face.
‘Jane’ talks about how the simple, everyday experience of grocery shopping is a challenge, as she feels people are looking at her skin, and think her psoriasis is contagious. Psoriasis is in fact an auto-immune disease and so is not contagious – one of the key messages IFPA want to focus on in 2020.
Watch Jane’s video: click here
‘Steve’ speaks about the sense of futility he sometimes feels because of the cycle of psoriasis flares, and the feeling of going through a “revolving door”.
Watch Steve’s video: click here
‘Becky’ talks about how having psoriasis as a child affected her confidence, and the ongoing challenge she feels now as a young adult.
Watch Becky’s video: click here
Alexandre Fevre, Vice President of Global Marketing, Psoriasis, at LEO Pharma, said of the campaign, “For many patients, psoriasis goes beyond just being a cosmetic challenge. Nearly 60 percent1 of people with psoriasis say their disease is a large problem in their everyday life.”
“This campaign draws attention to some of the everyday psoriasis challenges and gives a voice to psoriasis patients. We also hope it demonstrates LEO Pharma’s continued commitment to helping people achieve healthy skin.”
“As we say on our campaign website, the encouraging news for many patients is that there are ways to manage the condition. Not just treatments, but lifestyle changes too. If you or someone you know is experiencing #everydaypsoriasis challenges, consider approaching your doctor for advice.”
The #everydaypsoriasis videos can be viewed at www.everydaypsoriasis.com.
About psoriasis
Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide.1,2 About 80% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis.2 The symptoms of plaque psoriasis are itchy or painful, scaly, inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso.3 Psoriasis is characterized as mild when less than 3% of the body is affected and moderate to severe when more than 3% of the body is affected.4
References
1. Stern RS, et al. J Investig Dermatol Symp Proc. 2004;9(2):136-9.
2. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
3. Menter A et al. J Am Acad Dermatol 2008;58:826.
4. Armstrong AW et al. JAMA Dermatol. 2013;149(10):1180–1185.
To view this video from www.youtube.com, please give your consent at the top of this page.Our Manifesto Video
Contacts
Henrik Kyndlev
HDTDK@leo-pharma.com
+45 3140 6180
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference7.1.2026 13:00:00 CET | Pressemeddelelse
Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST. With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs. Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology. The J.P. Morgan Healthcare Con
LEO Pharma appoints Marika Murto to lead Global Product Strategy16.12.2025 09:00:00 CET | Pressemeddelelse
Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growth
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
